Symptoms can include upper abdominal pain, yellow discolouration of the skin and general widespread weakness in the body.

A groundbreaking non-surgical therapy at PGI has shown promising results for liver cancer patients, eliminating the need for transplants. This innovative treatment boasts a five-year mean survival ...

The summit, known for its pivotal discussions on advancements in cancer treatment, commenced with a focus on Hepatocellular ...

Advances in Cancer Treatment: How cutting-edge treatments are changing outcomes Cancer treatment is undergoing a ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where ...

Chronic liver disease (CLD) is a growing global health challenge, accounting for millions of deaths each year. Its major contributors include ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

The following is a summary of “End-of-life in Hepatocellular Carcinoma: How Palliative Care and Social Factors Impact Care and Cost,” published in the October 2024 issue of Gastroenterology by Goble ...